Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China

被引:0
|
作者
Li, Jiaming [1 ]
Zhang, Xinyue [2 ]
Wang, Rui [1 ]
Cao, Keyao [1 ]
Wan, Luhui [1 ]
Ren, Xu [1 ]
Ding, Jinxi [1 ,3 ]
Li, Wei [1 ,3 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Xinhua Hosp Zhejiang Prov, Hangzhou, Peoples R China
[3] China Pharmaceut Univ, Pharmaceut Market Access Policy Res Ctr, Nanjing, Peoples R China
关键词
National Centralized Drug Procurement policy; chemical pharmaceutical enterprise; R&D investment; influence mechanism; difference-in-difference analysis;
D O I
10.3389/fpubh.2024.1402581
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: This study aimed to evaluate the impact of the National Centralized Drug Procurement (NCDP) policy on chemical pharmaceutical enterprises' R&D investment and provide references for improving NCDP policy design and encouraging innovation in the pharmaceutical industry. Methods: Using the panel data of 102 Shanghai and Shenzhen A-share listed enterprises from 2016 to 2022 under the chemical pharmaceutical classification of Shenwan in Wind database as the research sample, this study developed difference-in-differences (DID) models on bid-winning and bid-non-winning enterprises, respectively, to evaluate the impact of NCDP policy on their R&D investment. In addition, this study tested the heterogeneity of bid-winning enterprises based on the bid success rate, the decline of drug price, and enterprise size. Results: The NCDP policy could encourage chemical pharmaceutical companies to increase R&D investment, but the low bid success rate and excessive drug price reduction would reduce their R&D enthusiasm, especially for small- and medium-sized enterprises. Discussion: It is suggested that the NCDP policy should be further improved: first, revise the bidding rule of the NCDP policy and increase the bid success rate so that more enterprises can win bids, and second, to solve the problem of excessive drug price reduction, evaluate the rationality of bid-winning prices, and introduce a two-way selection mechanism between medical institutions and supply enterprises. Integrate pharmacoeconomic evaluation into the NCDP rules to form a benign competition among enterprises. Third, attention should be paid to supporting policies for small- and medium-sized enterprises. By increasing procurement volume, shortening payment time limits, and increasing the proportion of advance payments, enterprises' cash flow shortages can be alleviated, thus achieving fairness and inclusiveness in the implementation of the NCDP policy.
引用
下载
收藏
页数:13
相关论文
共 26 条